From Breakthrough to Transformation: Redefining What’s Possible in Mental Health Treatment

A single clinical breakthrough changed everything for treatment-resistant depression. Now, NeoLumina is taking that science to a new frontier — applying it to conditions like anxiety, trauma, and eating disorders that have defied conventional therapies.

For decades, millions have faced a cruel paradox — access to treatment without relief.
People living with treatment-resistant depression often endure years of antidepressants, therapy, and searching for something — anything — that works.

Then, science revealed something extraordinary.

In a landmark clinical study of 269 patients, individuals who hadn’t responded to any previous therapy received a single 25 mg dose of psilocybin. The result?

Their depression lifted. Their hope returned.

For many, it was the first real change in years.

That single dose was more than medicine — it was a turning point.

At NeoLumina BioScience, we’re taking that breakthrough further — beyond depression and into the broader world of mental health disorders.

Our research is focused on developing natural psilocybin-based medicines designed not just to treat symptoms, but to transform lives.

For those battling anxiety, trauma, or eating disorders that have resisted every other therapy, our mission is clear:
to bring together science and humanity in a new model of care.

“Healing shouldn’t be a miracle — it should be the mission.”
— Dr. Gaetano Morello, CEO, NeoLumina BioScience

At NeoLumina, that’s the future we’re building — one where innovation meets empathy, and where hope becomes a clinical reality.

🎥 Watch Dr. Morello’s full message below.